Introduction {#section5-1756286419835708}
============

A meta-analysis of randomized controlled trials (RCTs) in patients treated with mechanical thrombectomy (MT) for acute ischaemic stroke (AIS) in the anterior circulation (AC) showed that the treatment effect of recanalization decreased over time, reaching non-significance at 7.3 h.^[@bibr1-1756286419835708]^ In those trials, patient selection was based primarily on symptom onset to groin puncture time (STG) of 6 h (MR CLEAN, EXTEND-IA, SWIFT-PRIME), 8 h (REVASCAT) and 12 h (ESCAPE). Further selection criteria were Alberta Stroke Program Early Computed Tomography Score (ASPECTS) thresholds, perfusion imaging and collateral status in four of the five trials. Recently, observational data of patients with an STG of up to 6.5 h suggested an even stronger decline of treatment effect, with an estimated 5.3% decreased probability of functional independence and a 2.2% increase in mortality at 3 months per hour increase from stroke onset to MT start.^[@bibr2-1756286419835708]^

Contrarily, two RCTs showed that advanced imaging is able to select patients up to 24 h after symptom onset benefiting from MT,^[@bibr3-1756286419835708],[@bibr4-1756286419835708]^ with a very strong treatment effect also in the late time window.^[@bibr5-1756286419835708]^ Although also here a decline in efficacy of the treatment effect was noted, the slope and time of the decline were very different from the studies mentioned above.^[@bibr6-1756286419835708]^ Therefore, the decline of treatment effect seems to be strongly influenced by patient selection, and the concept of a general time window with an uniform decline of efficacy has been challenged.^[@bibr7-1756286419835708],[@bibr8-1756286419835708]^ Furthermore, it remains unclear whether with increasing time from symptom onset to reperfusion (TTR) there is a cut-off time with deleterious treatment effect thereafter similar to intravenous thrombolysis (IVT) or if MT at a given time point simply remains futile and not cost-effective.^[@bibr9-1756286419835708],[@bibr10-1756286419835708]^

The aims of this study were (1) to evaluate the clinical effect of TTR; and (2) to assess the safety and technical efficacy of MT according to strata of TTR.

Methods {#section6-1756286419835708}
=======

Details on the BEYOND-SWIFT registry are in the public domain (ClinicalTrials.gov identifier: NCT03496064) and have been published previously.^[@bibr11-1756286419835708]^ Briefly, the registry is a retrospective, international, multicentre, non-randomized observational study to investigate the safety and efficacy of a CE-labelled market-release neurothrombectomy device (applied as initial devices) in AIS patients. An overview of included patients, rates of available follow-up data for each centre and ethical approval procedure can be found in [Supplementary Table 1](https://journals.sagepub.com/doi/suppl/10.1177/1756286419835708). Additionally, ethical approval was obtained in Bern for pooling and anonymized analyses of the registry data (KEK Bern, Bern, Switzerland ID 2018-00766).

Most patients in the registry (*n* = 2046) were treated for large-vessel AC strokes (*n* = 1832). Of the patients with known TTR (*n* = 1461), 1314 (89.9%) had documented 90-day follow up.

Variables and image analysis {#section7-1756286419835708}
============================

Local investigators categorized the site of occlusion into intracranial internal carotid artery, carotid-T/L, first/second/third segment of the middle cerebral artery (M1/M2/M3), and first/second segment of the anterior cerebral artery (A1/A2). The patients with large-vessel occlusion (LVO) in the posterior circulation and seven patients with missing information on occlusion site were excluded from this analysis. The post-procedural modified thrombolysis in cerebral infarction (mTICI) scale was operator-adjudicated at each centre or rated by an independent research fellow, depending on the applicable institutional standards (see [Supplementary Table 1](https://journals.sagepub.com/doi/suppl/10.1177/1756286419835708)). AC extracranial--intracranial tandem occlusion was defined as the presence of an intracranial LVO and \>90% cervical stenosis or occlusion. According to the modified version of the TICI scale, we rated mTICI2b as reperfusion of at least 50% of the initially occluded target territory.^[@bibr12-1756286419835708]^ ASPECTS was evaluated at each site (see [Supplementary Table 1](https://journals.sagepub.com/doi/suppl/10.1177/1756286419835708)) based on admission non-contrast computed tomography (CT) in 954/1461 (65.3%) cases and diffusion-weighted magnetic resonance imaging (MRI) in 505/1461 (34.6%) cases, with missing information in two cases. For clinical outcome evaluation, we assessed 3-month functional outcome applying the modified Rankin Scale (mRS) either in routinely scheduled clinical visits or standardized telephone interviews.

Statistical analysis {#section8-1756286419835708}
====================

The primary endpoint of this analysis was good functional outcome (mRS 0--2) at 90 days. Secondary and safety outcomes at 90 days consisted of excellent outcome (mRS 0--1), favourable outcome (mRS 0--3), all-cause mortality and symptomatic intracerebral haemorrhage (sICH), which was assessed at each centre, applying the European Co-operative Acute Stroke Study-II (ECASS II) criteria. Non-haemorrhagic neurological worsening was defined as a drop in the NIH Stroke Scale (NIHSS) ⩾4 between admission NIHSS and 24-h NIHSS without occurrence of sICH.^[@bibr13-1756286419835708]^

Univariate comparisons between three TTR strata (0--180 min, 180--360 min, \>360 min) were made using standard statistical measures \[Chi-squared test for categorical variables, Kruskal--Wallis H-test for non-normally continuous or ordinally scaled variables and analysis of variance (ANOVA) for independent normally distributed data\].

Association of TTR with all outcome parameters was assessed using multivariable logistic regression, adjusting for the following prespecified confounders: age (continuous), sex (categorical), NIHSS on admission (ordinal, adjusted odds ratio (aOR) per point increase), direct presentation *versus* transfer from another hospital (categorical), in-hospital stroke (categorical), wake-up stroke (categorical), tandem *versus* non-tandem (categorical, tandem defined as \>90% cervical stenosis or cervical occlusion), centre (categorical, contrast type: indicator, comparator: largest centre), ASPECTS (ordinal, aOR per point increase), IVT (categorical), risk factor hypertension (categorical), risk factor dyslipidaemia (categorical), risk factor smoking (categorical), risk factor previous stroke (categorical), risk factor diabetes (categorical), type of admission imaging (CT *versus* MRI, categorical) and successful reperfusion ⩾TICI2b. For mRS shift analysis, multivariable ordinal regression was used to assess the association of time to reperfusion with mRS at day 90 adjusting for the abovementioned categorical factors and continuous or ordinal covariates using a logit link function. A parallel lines test was used to check for proportional odds assumption. Patients with missing data were excluded from multivariate analysis.

Results {#section9-1756286419835708}
=======

Baseline characteristics {#section10-1756286419835708}
------------------------

Of 1832 patients in the registry, TTR was available in 1461 patients (1253 documented symptom onset, 203 last seen well) and all had documented final mTICI score. Overall, 404 patients had a TTR of more than 6 h and 371 of more than 7 h. Distribution of TTR and STG is depicted in [Supplementary Figures 1a](https://journals.sagepub.com/doi/suppl/10.1177/1756286419835708) and [1b](https://journals.sagepub.com/doi/suppl/10.1177/1756286419835708). Baseline characteristics and comorbidities are presented in [Table 1](#table1-1756286419835708){ref-type="table"}. Patients with late TTR had a higher rate of undocumented symptom onset, higher rate of wake-up stroke, lower rate of in-hospital stroke, were more likely to be transferred from another hospital, more often received MRI as the initial imaging modality, had a lower ASPECTS score and received IVT less often.

###### 

Baseline characteristics of all patients and according to time from symptom onset to reperfusion.

![](10.1177_1756286419835708-table1)

                                                    Symptom onset to reperfusion 0--180 min (n=192)   Symptom onset to reperfusion 180--360 min (n=876)   Symptom onset to reperfusion \>360 min (n=393)   *p*       All patients with available TTR (*n* = 1461)
  ------------------------------------------------- ------------------------------------------------- --------------------------------------------------- ------------------------------------------------ --------- ----------------------------------------------
  Clinical items                                                                                                                                                                                                     
  Age (years)                                       73 (IQR 63--82)                                   74 (IQR 60--81)                                     74 (IQR 62--82)                                  0.871     73 (IQR 61--82)
  Transfer from another hospital                    17 (8.9%)                                         283 (32.3%)                                         175 (44.5%)                                      \<0.001   475 (32.5%)
  Sex (female)                                      101 (52.6%)                                       444 (50.7%)                                         192 (48.9%)                                      0.679     737 (50.4%)
  NIHSS on admission                                17 (IQR 12--20)                                   16 (IQR 11--20)                                     16 (IQR 10--20)                                  0.135     16 (IQR 11--20)
  Prestroke independence                            177 (92.2%)                                       812 (93.2%)                                         361 (92.3%)                                      0.789     1350 (92.8%)
  Blood pressure systolic (mmHg)                    148 (SD 29)                                       151 (SD 29)                                         152 (SD 28)                                      0.309     150 (SD 28)
  Blood pressure diastolic (mmHg)                   81 (SD 21)                                        82 (SD 18)                                          82 (SD 24)                                       0.664     80 (SD 20)
  Admission glucose (mmol/L)                        6.4 (IQR 5.7--7.7)                                6.9 (IQR 5.8--8.1)                                  6.8 (IQR 5.8--8.3)                               0.156     6.6 (IQR 5.8--8.1)
  Quality of symptom onset                                                                                                                                                                                 \<0.001   
   − Noticed                                        186 (96.9%)                                       801 (91.4%)                                         266 (67.7%)                                                1253 (85.8%)
   − Last seen well                                 6 (3.1%)                                          73 (8.3%)                                           124 (31.6%)                                                203 (13.9%)
  Wake-up stroke                                    4 (2.1%)                                          27 (3.1%)                                           82 (20.9%)                                       \<0.001   113 (7.7%)
  In-hospital stroke                                15 (7.8%)                                         14 (1.6%)                                           7 (1.8%)                                         \<0.001   36 (2.5%)
  Medication                                                                                                                                                                                                         
  Antiplatelet                                                                                                                                                                                             0.558     
   − Monotherapy                                    51 (27.1%)                                        242 (29.8%)                                         97 (27.1%)                                                 390 (28.7%)
   − Dual Therapy                                   5 (2.7%)                                          15 (1.8%)                                           4 (1.1%)                                                   24 (1.8%)
  Statin                                            60 (33.5%)                                        237 (30.7%)                                         90 (25.9%)                                       0.137     387 (29.8%)
  Anticoagulation                                                                                                                                                                                          0.247     
   − None                                           157 (83.5%)                                       670 (82.4%)                                         308 (86.0%)                                                1135 (83.5%)
   − VKA                                            20 (10.6%)                                        102 (12.5%)                                         41 (11.5%)                                                 163 (12.0%)
   − NOAC                                           11 (5.9%)                                         41 (5.0%)                                           9 (2.5%)                                                   61 (4.5%)
  Risk factors                                                                                                                                                                                                       
  Diabetes                                          33 (17.2%)                                        151 (17.3%)                                         69 (17.6%)                                       0.990     253 (17.4%)
  Arterial hypertension                             139 (72.4%)                                       573 (65.9%)                                         258 (65.8%)                                      0.200     970 (66.7%)
  Dyslipidaemia                                     102 (53.1%)                                       450 (21.8%)                                         199 (51.0%)                                      0.892     751 (51.8%)
  Smoking                                           51 (27.7%)                                        255 (30.3%)                                         99 (25.9%)                                       0.278     405 (28.8%)
  Previous stroke                                   33 (17.2%)                                        120 (13.7%)                                         47 (12.1%)                                       0.253     200 (13.8%)
  Coronary artery disease                           31 (25.2%)                                        140 (22.3%)                                         61 (20.5%)                                       0.572     232 (22.1%)
  TOAST aetiology                                                                                                                                                                                          0.067     
   − Large artery                                   19 (10.0%)                                        110 (12.8%)                                         59 (15.3%)                                                 188 (13.1%)
   − Cardiac embolism                               100 (52.6%)                                       419 (48.6%)                                         168 (43.6%)                                                687 (47.8%)
   − Other specific                                 19 (10.0%)                                        50 (5.8%)                                           31 (8.1%)                                                  100 (7.0%)
   − Unknown                                        52 (27.4%)                                        283 (32.8%)                                         127 (33.0%)                                                462 (32.2%)
  Imaging                                                                                                                                                                                                            
  Imaging type                                                                                                                                                                                             0.016     
   − MRI                                            58 (30.2%)                                        289 (33.0%)                                         158 (40.3%)                                                505 (34.6%)
   − CT                                             134 (69.8%)                                       586 (67.0%)                                         234 (59.7%)                                                954 (65.4%)
  Hemisphere                                                                                                                                                                                               0.451     
   − Left                                           100 (54.3%)                                       418 (49.6%)                                         177 (46.3%)                                                695 (49.4%)
   − Right                                          82 (44.6%)                                        410 (48.7%)                                         197 (51.6%)                                                689 (48.9%)
   − Midline/bilateral                              2 (1.1%)                                          14 (1.7%)                                           8 (2.1%)                                                   24 (1.7%)
  Occlusion site                                                                                                                                                                                           0.259     
   − iICA                                           3 (1.6%)                                          31 (3.5%)                                           18 (4.6%)                                                  52 (3.6%)
   − Carotid-T/L                                    49 (25.5%)                                        195 (22.3%)                                         95 (24.2%)                                                 339 (23.2%)
   − M1                                             109 (56.8%)                                       535 (61.1%)                                         229 (58.3%)                                                873 (59.8%)
   − M2                                             28 (14.6%)                                        110 (12.6%)                                         51 (13.0%)                                                 189 (12.9%)
  Collaterals                                                                                                                                                                                              0.432     
   − 0                                              9 (20.5%)                                         49 (17.8%)                                          25 (20.2%)                                                 83 (18.7%)
   − 1                                              17 (38.6%)                                        109 (39.6%)                                         37 (39.8%)                                                 163 (36.8%)
   − 2                                              18 (40.9%)                                        117 (42.5%)                                         62 (50.0%)                                                 197 (44.5%)
  Tandem occlusion                                  22 (11.5%)                                        123 (14.1%)                                         79 (20.1%)                                       0.006     224 (15.3%)
  Dissection                                        3 (1.6%)                                          35 (4.0%)                                           21 (5.4%)                                        0.091     59 (4.0%)
  ASPECTS                                           9 (IQR 7--10)                                     8 (IQR 7--10)                                       8 (IQR 7--9)                                     \<0.001   8 (IQR 7--9)
  Treatment                                                                                                                                                                                                          
  IVT use                                           92 (47.9%)                                        522 (59.6%)                                         130 (33.1%)                                      \<0.001   744 (50.9%)
  Time from onset of symptoms to IVT needle (min)   85 (IQR 57--103)                                  130 (IQR 90--170)                                   180 (IQR 126--225)                               \<0.001   120 (IQR 83--170)
  Time from onset of symptoms to admission (min)    53 (IQR 39--69)                                   110 (IQR 70--173)                                   315 (IQR 240--477)                               \<0.001   133 (IQR 69--230)

TTR: time from symptom onset to reperfusion ASPECTS, Alberta Stroke Program Early Computed Tomography Score; CT, computed tomography; iICA, intracranial internal carotid artery; IVT, intravenous thrombolysis; M1, first segment of middle cerebral artery; M2, second segment of middle cerebral artery; MRI, magnetic resonance imaging; NIHSS, National Institute of Health Stroke Scale; NOAC, non-vitamin-K antagonist oral anticoagulant; TOAST, Trial of ORG 10172 in Acute Stroke Treatment; VKA, vitamin K antagonist.

Outcome {#section11-1756286419835708}
=======

On unadjusted analysis, better long-term outcomes were observed in patients with short TTR as indicated by significantly higher rates of mRS 0--2 (55.0% *versus* 46.8% *versus* 38.1%, *p* = 0.001, [Table 2](#table2-1756286419835708){ref-type="table"}) and mRS 0-1 (39.2% *versus* 28.4% *versus* 24.9%, *p* = 0.003). Also, NIHSS at 24 h was lower and median NIHSS improvement at 24 h greater in shorter TTR (*p* \< 0.001; [Supplementary Figures 2](https://journals.sagepub.com/doi/suppl/10.1177/1756286419835708) and [3](https://journals.sagepub.com/doi/suppl/10.1177/1756286419835708)). However, mortality (19.3% *versus* 22.3% *versus* 23.7%, *p* = 0.520) did not differ significantly. The overall incidence of non-haemorrhagic neurological worsening was 7.8% (95% CI 6.4--9.2%), with no significant differences among TTR strata (*p* = 0.138). Rate of sICH was highest in the medium TTR stratum (3.1% *versus* 7.7% *versus* 5.4%, *p* = 0.04; see [Table 4](#table4-1756286419835708){ref-type="table"}).

###### 

Outcome data comparing patients with large-vessel occlusion according to time from symptom onset to reperfusion.

![](10.1177_1756286419835708-table2)

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                  Symptom onset to reperfusion 0--180 min\   Symptom onset to reperfusion 180--360 min\   Symptom onset to reperfusion \>360 min\   *p*       All patients with available TTR (*n* = 1461)
                                  (*n* = 192)                                (*n* = 876)                                  (*n* = 393)                                         
  ------------------------------- ------------------------------------------ -------------------------------------------- ----------------------------------------- --------- ----------------------------------------------
  Outcome                                                                                                                                                                     

  mRS 0--1 at 3 months            67 (39.2%)                                 224 (28.4%)                                  88 (24.9%)                                0.003     379 (28.8%)

  mRS 0--2 at 3 months            94 (55.0%)                                 369 (46.8%)                                  135 (38.1%)                               0.001     598 (45.5%)

  mRS 0--3 at 3 months            117 (68.4%)                                484 (61.3%)                                  189 (53.4%)                               0.002     790 (60.1%)

  Mortality at 3 months           33 (19.3%)                                 176 (22.3%)                                  84 (23.7%)                                0.520     293 (22.3%)

  NIHSS at 24 h                   5 (IQR 2--13)                              8 (IQR 3--15)                                10 (IQR 4--17)                            \<0.001   8 (IQR 3--15)

  Delta NIHSS admission -- 24 h   9 (IQR 5--15)                              6 (IQR 1--11)                                3 (IQR 0--7)                              \<0.001   5 (IQR 1--11)

  Non-haemorrhagic worsening      7 (4.2%)                                   54 (8.0%)                                    27 (9.4%)                                 0.138     88 (7.8%)
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

TTR: time from symptom onset to reperfusion; Delta NIHSS, difference in NIHSS between NIHSS at admission compared to 24 h; mRS, modified Rankin Scale; NIHSS, National Institute of Health Stroke Scale.

TTR per hour increase was a significant factor related to mRS 0--2 (aOR 0.933, 95% CI 0.887 --0.981; [Table 3](#table3-1756286419835708){ref-type="table"}), mRS 0--1 (aOR 0.929, 95% CI 0.877--0.985) and mRS 0--3 (aOR 0.955, 95% CI 0.911--1.000) in multivariable binary logistic regression analysis adjusting for prespecified confounders outlined in the methods section ([Figure 1](#fig1-1756286419835708){ref-type="fig"}). Associations for non-haemorrhagic neurological worsening approached significance (aOR 1.068, 95% CI 0.996--1.144) and were non-significant for all-cause mortality at 3 months (aOR 0.988, 95% CI 0.933--1.046) and sICH (aOR 1.020, 95% CI 0.927--1.123). Per hour delay of reperfusion there was a 1.5% decreased probability of good functional outcome ([Figure 2](#fig2-1756286419835708){ref-type="fig"}). The point estimates were similar and remained significant for mRS 0--2 and mRS 0--1 in the subgroup of patients with TTR of more than 6 h ([Supplementary Table 2](https://journals.sagepub.com/doi/suppl/10.1177/1756286419835708)).

###### 

Analysis was done using time to reperfusion information in minutes, but association of TTR per hour increase with outcome data comparing patients with large-vessel occlusion in the anterior circulation is reported. Analysis was done using multivariable binary or ordinal logistic regression analysis adjusting for prespecified confounders outlined in the methods section for TTR per hour increase except aOR for successful reperfusion, which was analysed without successful reperfusion as variable.

![](10.1177_1756286419835708-table3)

  Outcome                                                    Unadjusted odds ratio (95% CI)   Adjusted odds ratio (95% CI)
  ---------------------------------------------------------- -------------------------------- ------------------------------
  mRS 0--1 at 3 months                                       0.928 (0.886--0.971)             0.929 (0.877--0.985)
  mRS 0--2 at 3 months                                       0.928 (0.892--0.965)             0.933 (0.887--0.981)
  mRS 0--3 at 3 months                                       0.951 (0.918--0.986)             0.955 (0.911--1.000)
  Reperfusion at intervention (mTICI ⩾2B)                    0.945 (0.906--0.985)             0.934 (0.885--0.984)
  mRS at 3 months (shift)                                    1.046 (1.014--1.078)             1.038 (1.001--1.077)
  Non-haemorrhagic worsening at 24 h                         1.053 (0.998--1.110)             1.068 (0.996--1.144)
  Mortality at 3 months                                      1.018 (0.979--1.058)             0.988 (0.933 -- 1.046)
  Symptomatic intracranial haemorrhage ECASS II definition   1.008 (0.944--1.076)             1.020 (0.927--1.123)

ECASS II, European Co-operative Acute Stroke Study-II; mRS, modified Rankin Scale; mTICI, modified treatment in cerebral ischaemia.

![Day 90 functional outcome at 3 months according to time to reperfusion.\
Distribution of mRS scores at 3 months, according to time to reperfusion strata. Analysis was done using multivariable binary logistic regression analysis adjusting for prespecified confounders outlined in the methods section for TTR per hour increase. The thick green line proposed by Goyal and colleagues indicates a highly significant beneficial treatment effect with higher rate of the primary outcome mRS 0--2 (aOR 0.933, 95% CI 0.887--0.981, *p* = 0.007). The thin green line indicates a significant beneficial treatment effect with higher rate of mRS 0--1 (aOR 0.929, 95% CI 0.877--0.985, *p* = 0.013) and mRS 0--3 (aOR 0.955, 95% CI 0.911--1.000, *p* = 0.049). The thin red line indicates a beneficial, but non-significant, treatment effect for mortality (aOR 0.988, 95% CI 0.933--1.046, *p* = 0.680).\
mRS, modified Rankin scale.](10.1177_1756286419835708-fig1){#fig1-1756286419835708}

![Probability of good functional outcome (mRS 0--2) with margins plot, including 95% confidence intervals.\
For this analysis, time to reperfusion was used as a continuous variable and multivariable binary logistic regression analysis was performed, adjusting for prespecified confounders outlined in the methods section. Per hour delay of reperfusion there was a 1.5% decreased probability of good functional outcome.\
mRS, modified Rankin scale.](10.1177_1756286419835708-fig2){#fig2-1756286419835708}

On ordinal regression analysis adjusting for prespecified confounders outlined in the methods section, TTR per hour increase significantly worsened long-term functional outcome (aOR 1.038, 95% CI 1.001--1.077). However, the assumption of proportional odds was violated, as indicated by the parallel lines test (*p* \< 0.001). Nevertheless, the aOR lies in the same range as indicated by dichotomized multivariable binary logistic regression analysis and the parallel lines test may be overly sensitive when continuous explanatory variables are present or output variable number or sample size are large.^[@bibr14-1756286419835708]^

STG per hour increase was neither related to long-term functional outcome nor to mortality ([Supplementary Table 3](https://journals.sagepub.com/doi/suppl/10.1177/1756286419835708)) in multivariate analysis.

Tolerability and efficacy {#section12-1756286419835708}
=========================

Treatment metrics with efficacy and tolerability outcomes are presented in [Table 4](#table4-1756286419835708){ref-type="table"}. Reperfusion by IVT and/or MT defined as ⩾TICI2b was successful in 1277 patients (87.4%). On univariate analysis, patients with late TTR had lower rates of successful and excellent reperfusion, more extracranial stenting and higher rate of general anaesthesia. Additionally, complication rate, number of passes and intervention duration were higher in late TTR. In multivariable logistic regression analysis adjusting for prespecified confounders outlined in the methods section, TTR per hour increase was a significant factor related to successful reperfusion (TICI⩾2b, aOR 0.934, 95% CI 0.885--0.984), excellent reperfusion (TICI 3, aOR 0.924, 95% CI 0.883-0.967) and number of passes (aOR 1.092, 95% CI 1.048-1.138), but not a significant factor for overall complication occurrence (aOR 1.008, 95% CI 0.950-1.067).

###### 

Tolerability and efficacy data comparing patients with large-vessel occlusion according to symptom onset to reperfusion time.

![](10.1177_1756286419835708-table4)

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                        Symptom onset to reperfusion 0--180 min\   Symptom onset to reperfusion 180--360 min\   Symptom onset to reperfusion \>360 min\   *p*       All patients with available TTR (*n* = 1461)
                                                        (*n* = 192)                                (*n* = 876)                                  (*n* = 393)                                         
  ----------------------------------------------------- ------------------------------------------ -------------------------------------------- ----------------------------------------- --------- ----------------------------------------------
  Efficacy                                                                                                                                                                                          

  mTICI 3                                               111 (57.8%)                                423 (48.3%)                                  152 (38.7%)                               \<0.001   686 (47.0%)

  mTICI 2b, 2c or 3                                     187 (97.4%)                                774 (88.4%)                                  316 (80.4%)                               \<0.001   1277 (87.4%)

  Time from onset of symptoms to groin puncture (min)   117 (IQR 94--135)                          205 (IQR 170--245)                           382 (IQR 332--561)                        \<0.001   225 (IQR 162--309)

  Time from groin puncture to reperfusion (min)         30 (IQR 21--42)                            47 (IQR 30--75)                              54 (IQR 33--88)                           \<0.001   45 (IQR 30--72)

  General anaesthesia                                   70 (36.5%)                                 484 (55.6%)                                  225 (57.5%)                               \<0.001   779 (53.6%)

  Additional intra-arterial thrombolytics               7 (3.7%)                                   90 (10.3%)                                   18 (4.6%)                                 \<0.001   115 (7.9%)

  Balloon guiding catheter                              89 (46.4%)                                 469 (53.6%)                                  223 (56.7%)                               0.061     781 (53.5%)

  Intermediate aspiration catheter                      97 (54.8%)                                 405 (50.9%)                                  187 (51.7%)                               0.640     689 (51.6%)

  Manoeuvre count                                       1 (IQR 1--2)                               1 (IQR 1--2)                                 2 (IQR 1--3)                              \<0.001   

  Intracranial stenting                                 2 (1.0%)                                   19 (2.2%)                                    5 (1.3%)                                  0.382     26 (1.8%)

  Extracranial stenting                                 14 (7.3%)                                  92 (10.5%)                                   57 (14.5%)                                0.022     163 (11.2%)

  Safety                                                                                                                                                                                            

  sICH ECASS II definition                              6 (3.1%)                                   67 (7.7%)                                    21 (5.4%)                                 0.040     94 (6.5%)

  Systemic bleeding                                     1 (2.1%)                                   11 (3.4%)                                    0 (0.0%)                                  0.098     12 (2.4%)

  Craniectomy                                           3 (1.6%)                                   29 (3.3%)                                    14 (3.6%)                                 0.389     46 (3.2%)

  Non-haemorrhagic worsening                            7 (4.2%)                                   54 (8.0%)                                    27 (9.4%)                                 0.138     88 (7.8%)

  Any interventional complication of:                   14 (7.3%)                                  118 (13.5%)                                  59 (15.0%)                                0.029     191 (13.1%)

   − Vasospasms                                         4 (28.6%)                                  29 (24.4%)                                   17 (27.9%)                                          49 (25.7%)

   − Cervical dissection                                3 (21.4%)                                  28 (23.5%)                                   8 (13.1%)                                           38 (19.9%)

   − Perforation                                        2 (14.3%)                                  9 (7.6%)                                     5 (8.2%)                                            16 (8.4%)

   − Other                                              2 (14.3%)                                  16 (13.4%)                                   9 (14.8%)                                           26 (13.6 %)

   − Emboli to new territory                            3 (21.4%)                                  37 (31.1%)                                   22 (36.1%)                                          62 (32.5%)
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

TTR: time to reperfusion; LVO, large-vessel occlusion; mTICI, modified treatment in cerebral ischaemia; sICH, symptomatic intracranial haemorrhage according to European Co-operative Acute Stroke Study-II definition.

Among patients with TTR of more than 7 h, successful reperfusion significantly increased the odds of mRS 0--2 (aOR 7.879, 95% CI 2.325--26.699) and mRS 0--1 (aOR 5.249, 95% CI 1.301--21.183). Non-significant associations were found for all-cause mortality at day 90 (aOR 0.414, 95% CI 0.156--1.099) and sICH (aOR 1.102, 95% CI 0.108--11.232) in multivariable binary logistic regression analysis adjusting for prespecified confounders outlined in the methods section ([Figure 3](#fig3-1756286419835708){ref-type="fig"}).

![Adjusted odds ratio of successful reperfusion (mTICI⩾2b/3) for outcome parameters.\
Adjusted odds ratio of successful reperfusion (mTICI⩾2b/3) for outcome parameters stratified for patients with time to reperfusion from symptom onset (TTR) of less or more than 7 h.\
mRS, modified Rankin scale; sICH, symptomatic intracranial haemorrhage; TTR, time to reperfusion from symptom onset.](10.1177_1756286419835708-fig3){#fig3-1756286419835708}

Discussion {#section13-1756286419835708}
==========

In this retrospective multicentre registry dataset we analysed the impact of TTR on 3-month functional outcome as well as tolerability and efficacy of MT with the following main findings: (1) TTR is an independent factor related to long-term functional outcome with an estimated 1.5% decreased probability of good functional outcome per hour delay. Additionally, fast TTR is associated with early neurologic recovery. (2) With increasing TTR, interventional procedures become technically less effective; however, increasing TTR was not significantly related to mortality or sICH.

In this analysis we chose to analyse TTR rather than STG, because when analysing STG many patients who are subjected to MT but never actually achieve reperfusion are part of the analysis, which weakens the true TTR effect because those patients are subjected to the potential downsides of MT without having the chance to benefit from it. However, it is rather successful reperfusion than *intention to treat* that is a major predictor of outcome, with every 10% increase in the rates of successful reperfusion accounting for an estimated 17% increase in the probability of achieving excellent outcomes.^[@bibr15-1756286419835708]^ Our finding that STG was not a significant factor related to long-term functional outcome when adjusting for confounders confirms this view. Second, STG in patients who do not achieve reperfusion reflects other evidence-based treatments like earlier IVT, medical treatment or stroke unit care which might have biased the effect ascribed to STG. Contrarily to Al Sultan and Hill,^[@bibr16-1756286419835708]^ arguing for an imprecise measurement of TTR, we hence favour TTR to be a more precise and meaningful parameter compared to STG. This view is in line with the 'time-reset effect', arguing for the quickest possible reperfusion once imaging identifies relevant salvageable tissue,^[@bibr7-1756286419835708]^ rendering time from imaging to reperfusion the main time dependence because of the used imaging selection.

Our analysis has several complementary features to published data.^[@bibr1-1756286419835708],[@bibr2-1756286419835708],[@bibr8-1756286419835708]^ First, whereas STG was limited in two of the studies, we had no such restriction including patients more than 40 h after symptom onset. Second, due to a larger sample size and good data quality, we were able to correct for several confounders that might have influenced the strong effect seen with TTR. Third, because of a markedly higher recanalization rate, our estimates probably more reliably reflect the true effect of TTR as compared to STG analysis for the reasons mentioned above.

In comparison to the association of TTR times with functional outcome in the HERMES (Highly Effective Reperfusion Evaluated in Multiple Endovascular Stroke Trials) meta-analysis of previous RCTs, our results suggest that the association for TTR is less pronounced in real-world patients. We explain those findings by advances in imaging-based patient selection better identifying patients benefiting from MT. For example, a patient with complete fluid-attenuated inversion recovery demarcation of M2-occlusion might have been denied MT, although presenting 4.5 h after symptom onset.

Since almost all RCTs used some kind of imaging selection or other inclusion criteria, the true decline of TTR treatment effect when subjecting all AIS patients with a target LVO in the AC has and will probably never been elucidated. However, it is very important to keep in mind that the slope of decline in efficacy is strongly influenced by patient selection,^[@bibr7-1756286419835708]^ and treatment effect may be distinct also in late TTR as shown by recent DAWN and DEFUSE-3 RCTs.^[@bibr3-1756286419835708],[@bibr4-1756286419835708]^ In this registry, we observed heterogeneous aOR of TTR on good functional outcome for each centre ([Supplementary Table 5](https://journals.sagepub.com/doi/suppl/10.1177/1756286419835708)), probably due to different approaches to patient selection.

The relative merits of achieving successful reperfusion for dichotomizations of the mRS scale, mortality and sICH were comparable between patients reperfused before and after 7 h ([Figure 3](#fig3-1756286419835708){ref-type="fig"}), with significant effect of reperfusion on mRS 0--2 and mRS 0--1 also in TTR of more than 7 h. However, due to large confidence intervals, findings only approached significance for mortality in patients reperfused after 7 h. In patients with STG of more than 6 h, the rates of 3-month mRS categories and mortality were roughly comparable to DAWN and DEFUSE-3 MT patients ([Supplementary Figure 4](https://journals.sagepub.com/doi/suppl/10.1177/1756286419835708)).^[@bibr3-1756286419835708],[@bibr4-1756286419835708]^ This finding confirms that tertiary stroke centres apply the change from a merely time-based approach to MT towards a tissue-based protocol in late-presenting patients correctly, with similar benefits of reperfusion also in late TTR. Even the participating tertiary stroke centres performed CT in 80/154 (52%) of patients with TTR of more than 8 h, underlining the importance of a CT-based algorithm to select patients for MT in the late time window as an alternative when MRI is not available.^[@bibr17-1756286419835708]^

The recanalization rate of 82.8% of the whole AC registry is similar to recent observational studies with smaller patient numbers,^[@bibr18-1756286419835708][@bibr19-1756286419835708]--[@bibr20-1756286419835708]^ but higher compared to a meta-analysis that included older MT devices^[@bibr20-1756286419835708]^ and recent registries.^[@bibr2-1756286419835708],[@bibr8-1756286419835708]^ The mortality rate of about 22% is almost identical to the published data; however, contrarily to a recent meta-analysis we found no increase in mortality when early and late recanalization were compared.^[@bibr20-1756286419835708]^ The rate of complications in patients reperfused after 6 h was 15.0%, similar to rates previously reported,^[@bibr21-1756286419835708]^ and matched the frequency of complications observed in patients reperfused between 3 and 6 h.^[@bibr21-1756286419835708]^ In regards to serious complications in patients reperfused after 7 h, we observed three perforations with no associated mortality. Patients with an unsuccessful recanalization had higher complication rates (22.5% *versus* 10.6%, *p* \< 0.001).

Although the median time interval for when a patient was last known to be well and the occurrence of treatment was about 13 h in DAWN and 12 h in DEFUSE-3, the actual number of patients with warranted late MT treatment was quite low due to the high percentage of wake-up stroke.^[@bibr3-1756286419835708],[@bibr4-1756286419835708]^ Our registry did have a higher percentage of truly late-presenting patients with documented symptom onset. However, patients treated very late after symptom onset were scarce (see [Supplementary Table 4](https://journals.sagepub.com/doi/suppl/10.1177/1756286419835708)), but we still found a beneficial effect of MT also in late TTR. Further evidence needs to definitely confirm tolerability and efficacy of MT in this scenario and establish reliable imaging criteria for patient selection.

Limitations {#section14-1756286419835708}
-----------

Being a single-arm multicentre retrospective registry, this study has associated limitations. Most importantly, patient selection for MT was not specified or centre-specific. No control group of medical management only was available. No core lab adjudication was performed for neuroradiological variables like mTICI score and ASPECTS. Subgroup analyses were generally confined to small cohorts, introducing a large uncertainty of the presented with wide confidence intervals. Another limitation, but also a strength, of this study is heterogeneous patient selection by each centre based on either CT or MRI and clinical criteria, which allows generalizability at least to tertiary stroke centres.

Conclusion {#section15-1756286419835708}
==========

TTR is an independent factor related to long-term functional outcome, with an estimated 1.5% decreased probability of good functional outcome per hour delay in the selected patients of this registry. However, the timing and slope of decline in efficacy are strongly influenced by (imaging) patient selection, hence a general assumption regarding this decline should be questioned. STG was not a significant factor related to long-term functional outcome. With increasing TTR, interventional procedures become technically less effective. Efforts should be made to shorten TTR through optimized prehospital and in-hospital pathways.
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